Palisade Bio news
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan.
On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares of the Company’s common stock as an i
Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.
Ladenburg Thalmann &
- NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study
- Newsoara to fully fund Phase 3 program in China
- Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio
Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET.
Participating from the Palisade
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022.
As part of the conference, a video webcast of the Company’s presentation will be available for viewing on-demand for those registered to att
- Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery
- Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EST
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeon
Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team as Senior Vice President, Operations and Strategic Development. Rob is an accomplished industry veteran with a proven track record of execution who will be responsible for internal operations helping set corporate strategy.
“Rob’s leader
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor meetings during that period and talking about their lead program, LB1148. LB1148 has shown sig